VIR NASDAQ
Vir Biotechnology, Inc.
1W: +8.1%
1M: +3.6%
3M: +24.8%
YTD: +85.9%
1Y: +91.0%
3Y: +34.6%
5Y: -71.5%
$11.57
+0.53 (+4.80%)
After Hours: $11.32 (-0.25, -2.12%)
Weekly Expected Move ±7.6%
$9
$10
$11
$11
$12
Credit Risk of going bust: lower than 56% of companies Debt: 4.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 99.4%), Vir Biotechnology, Inc. would be worth roughly what it owes.
Total debt $93.3M against a stock market value of $1.87B.
Distance to default 5.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $46.6M (short-term plus half of long-term), stock volatility 63.0%; Altman Z'' 2.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.07 (down 99.4%), Vir Biotechnology, Inc. would be worth roughly what it owes.
Total debt $93.3M against a stock market value of $1.87B.
Distance to default 5.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $46.6M (short-term plus half of long-term), stock volatility 63.0%; Altman Z'' 2.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (63)
Vir Biotechnology, Inc. (VIR) – What Are Investment Firms Thinking About This Stock?
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Vir jumps on Gilead licensing deal worth up to $1.9B for cancer drugs
Vir Biotechnology (NASDAQ:VIR) Shares Climb 6.1% – Here’s What Happened
Vir Biotechnology appoints David Liu as chief medical officer
Vir Biotechnology names Aziz Sawaf as CFO
Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR
Jupiter Topco LLC Acquires Shares of 54,789 Vir Biotechnology, Inc. $VIR
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $21.57 Consensus Price Target from Analysts
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR
Vir Biotechnology climbs 9% amid post-earnings uptrend
Vir outlines ECLIPSE 1 top-line in Q4 2026 while projecting cash runway into the second half of 2028
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.
Vir Biotechnology anticipates VIR-5500 Phase III start in 2027 while expecting cash runway into 2H 2028
Vir Biotechnology, Inc. Q1 2026 Earnings Call Summary
Vir (VIR) Q1 2026 Earnings Call Transcript
Earnings Scheduled For May 6, 2026
Vir Biotechnology GAAP EPS of -$0.85 misses by $0.93
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000
Backer Marianne De Sells 72,559 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
Aberdeen Group plc Sells 135,688 Shares of Vir Biotechnology, Inc. $VIR
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of “Moderate Buy” by Brokerages
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells $199,540.00 in Stock
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $20.44
Vir Biotechnology, Inc. $VIR Shares Sold by Citigroup Inc.
I started reading SEC 8-K filings before every trade. Here's 3 times it actually mattered this week
HC Wainwright Issues Optimistic Outlook for VIR Earnings
Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Vir Biotechnology to Participate in Upcoming Investor Conferences
Vir Biotechnology prices $150M stock offering
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Vir Biotechnology launches $200M public stock offering
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
These Analysts Boost Their Forecasts On Vir Biotechnology
Biggest stock movers Tuesday: HIMS, VIR, and more
Vir Biotechnology outlines $1.7B Astellas collaboration and anticipates cash runway into Q2 2028 as VIR-5500 advances
What's Happening With VIR Stock?
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Vir surges on up to $1.7B deal with Astellas to advance prostate cancer asset
Vir Biotechnology GAAP EPS of -$0.31 beats by $0.10, revenue of $64.07M beats by $44.16M
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates
Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Here are the major earnings after the close Monday
Vir Biotechnology Q4 2025 Earnings Preview
Catalyst Watch: Nvidia blockbuster, JPMorgan event, and reactions to the tariff reset
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $17.00 Consensus Price Target from Brokerages
Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares of Stock
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of “Moderate Buy” by Brokerages
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $17.30 Consensus Price Target from Brokerages